Pharmacogenomic predictors of citalopram treatment outcome in major depressive disorder.

ABSTRACT:

Objectives

A significant proportion of patients with major depressive disorder (MDD) do not improve following treatment with first-line antidepressants and, currently, there are no objective indicators of predictors of antidepressant response. The aim of this study was to investigate pre-treatment peripheral gene expression differences between future remitters and non-responders to citalopram treatment and identify potential pharmacogenomic predictors of response.

Methods

We conducted a gene expression study using Affymetrix HG-U133 Plus2 microarrays in peripheral blood samples from untreated individuals with MDD (N = 77), ascertained at a community outpatient clinic, prior to an 8-week treatment with citalopram. Gene expression differences were assessed between remitters an

SUBMITTER: Mamdani F 

PROVIDER: S-EPMC5293541 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature